Citadel Advisors’s Immunocore IMCR Stock Holding History
Bought
Maintained
Sold
Other funds holding IMCR
KCM
Citadel Advisors's IMCR Position: Q3 2026 in Review
Citadel Advisors reduced its Immunocore (IMCR) stake by 53% in Q3 2026, selling an estimated $10.2M and leaving 267,325 shares worth $8.1M. The position accounts for ﹤0.01% of the portfolio, ranked #3999.
Citadel Advisors first reported a position in IMCR in Q1 2021 and has held it in 23 quarters since. The position peaked at $18M in Q2 2026. 130 funds tracked by Wall St. Rank hold IMCR as of Q3 2026.
- Citadel Advisors held 267,325 shares of Immunocore worth $8.1M as of Q3 2026.
- Citadel Advisors sold 299,436 Immunocore shares in Q3 2026, an estimated $10.2M.
- Immunocore made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #3999 holding.
- Citadel Advisors first reported a position in Immunocore in Q1 2021 and has held it in 23 quarters since.
- Citadel Advisors's Immunocore position peaked at $18M in Q2 2026.
- 130 funds tracked by Wall St. Rank held Immunocore as of Q3 2026.
Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.